Magrolimab (anti-CD47): Daver et al. recently published the results of a phase Ib trial (NCT03248479) investigating the safety and efficacy of magrolimab in association with AZA in previously untreated AML ineligible for chemotherapy [138]. Here, CD47 is linked to acute myeloid leukemia.